Stockwinners Market Radar for December 04, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:02 EST Galiano Gold announces buyout of offtake agreement - Galiano Gold has terminated its gold purchase and sale agreement with Red Kite for total cash consideration of $13M. Under the agreement, the company had been required to sell 100% of gold production from the Asanko Gold Mine, up to a maximum of 2.2 million ounces, at a spot price selected by Red Kite during a nine-day quotational period following shipment of gold from the AGM. At the time of termination, the AGM had delivered 1,706,407 gold ounces to Red Kite under the agreement. Over the past two years, during a period of elevated gold prices and volatility, the differential between the AGM's realized gold price under the agreement and the spot price of gold on the gold delivery date, has resulted in a discount of approximately 2%.

16:58 EST Five Below up 11% at $116.72 after Q3 earnings beat, FY24 guidance raise

16:57 EST Merus gets FDA approval of BIZENGRI in NRG1+ Pancreatic Adenocarcinoma, NSCLC - The company states: "Merus announced that the FDA approved BIZENGRI(R) (zenocutuzumab-zbco), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non-small cell lung cancer, or NSCLC, that are advanced unresectable or metastatic and harbor a neuregulin 1, NRG1, gene fusion who have disease progression on or after prior systemic therapy. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). BIZENGRI(R) has a Boxed WARNING for Embryo-Fetal Toxicity and warnings for infusion-related reactions, hypersensitivity and anaphylactic reactions, interstitial lung disease/pneumonitis, and left ventricular dysfunction. We believe this approval fills an important need for patients with NRG1+ cancer who have not previously had treatment options approved to specifically target this driver. BIZENGRI(R) (zenocutuzumab-zbco) 20 mg/mL Injection for Intravenous Use is expected to be available to patients in the coming weeks. The approval of BIZENGRI(R) is based on data from the eNRGy trial, a multicenter, open-label clinical trial that enrolled patients with NRG1+ pancreatic adenocarcinoma or NRG1+ NSCLC that is advanced unresectable or metastatic and had disease progression on or after prior systemic therapy. In patients with NRG1+ pancreatic adenocarcinoma, BIZENGRI(R) demonstrated an ORR of 40% (95% CI, 23%-59%). DOR in NRG1+ pancreatic adenocarcinoma ranged from 3.7 months to 16.6 months. In the same trial, patients with NRG1+ NSCLC (n=64) who were treated with BIZENGRI(R) demonstrated an overall response rate of 33%. The median DOR in NRG1+ NSCLC was 7.4 months (95% CI, 4.0-16.6). Response rates were measured using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review. In the pooled safety population (N=175), the most common (greater than or equal to10%) adverse reactions were diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions (IRR), dyspnea, rash, constipation, vomiting, abdominal pain, and edema. The most common Grade 3 or 4 laboratory abnormalities (greater than or equal to2%) were increased gamma-glutamyltransferase, decreased hemoglobin, decreased sodium, decreased platelets, increased aspartate aminotransferase, increased alanine aminotransferase, increased alkaline phosphatase, decreased magnesium, decreased phosphate, increased activated partial thromboplastin time, and increased bilirubin."

16:44 EST Mawson Infrastructure responds to media report regarding Chapter 11 petition - Mawson Infrastructure said that a media outlet earlier falsely reported that the company has filed a voluntary Chapter 11 petition. The company said, "Rather, entities in Australia, including W Capital Advisors Pty Ltd as trustee for the W Capital Advisors Fund and Marshall Investments MIG Pty Ltd as trustee for the Marshall Investments MIG Trust, have filed an involuntary Chapter 11 petition against the Company. The Company has not yet been formally served with an involuntary petition; however, if served, the Company's Board of Directors intend to vigorously defend the Company against such a filing to the full extent of the law. Mawson expects to continue to operate as usual and execute its business plan accordingly. The Company has previously corresponded with W Capital Advisors Pty Ltd as trustee for the W Capital Advisors Fund and its representatives, and the Company has expressed significant concerns about W Capital Advisors Pty Ltd as trustee for the W Capital Advisors Fund and James Manning, a former board director and executive of the Company, being related parties. Neither W Capital nor James Manning have responded to the Company's concerns in a manner satisfactory to the Company. James Manning is also the subject of an investigation by the Company's Audit Committee related to his dealings with W Capital Advisors Pty Ltd as trustee for the W Capital Advisors Fund - among several other matters - including current litigation with an entity related to Manning, Vertua Property Inc. ("Vertua"), regarding alleged self-dealing, breach of contract, and tortious interference with a business relationship. Notably, Vertua is a company not only related to James Manning, but also affiliated with Darron Wolter of W Capital Advisors Pty Ltd as trustee for the W Capital Advisors Fund. The Company filed a complaint in The Court of Common Pleas of Mercer County, Pennsylvania (file number 2024-2332) on October 17, 2024 against Vertua as landlord for the Company's Sharon, PA property for breach of the lease agreement and wrongful termination of the lease, as well as for tortious interference with a business relationship. The Company is seeking reinstatement of the lease, compensatory damages, disgorgement of revenue, and exemplary and punitive damages, as well as reimbursement for its costs and litigation expenses. As per the Company's most recent 10-Q filing on November 14, 2024, W Capital Advisors Pty Ltd as trustee for the W Capital Advisors Fund and Marshall Investments MIG Pty Ltd as trustee for the Marshall Investments MIG Trust had filed proceedings in Australia, and the Company believes that these entities are using such proceedings in an improper attempt to gain leverage in ongoing legal disputes between the parties. The Company believes that the filing of the involuntary Chapter 11 petition is a continuation of this pattern. The Company has previously reported through an 8-K filing on March 29, 2024 that the Company may seek to exit certain or all of its entities and holdings in Australia. The Company currently operates facilities in the United States of America and does not have any operating sites or assets in Australia."

16:35 EST Treace announces cases using RedPoint Intelliguide PSI with Adductoplasty - Treace Medical Concepts announced the successful completion of the first cases combining IntelliGuide PSI technology with the Adductoplasty System for a CT-based, patient specific correction personalized to the patient's unique midfoot deformity. IntelliGuide PSI, incorporating RedPoint technology, is the first and only patient-specific cut guide system available for correction of bunion and/or midfoot deformities in the U.S. IntelliGuide PSI provides an AI-enabled software approach to convert a patient's CT-scan to a pre-operative surgical plan and produce a 3D-printed cut guide specific to the patient's deformity for efficient and personalized intra-operative guidance. It is estimated that midfoot deformities, such as metatarsus adductus, may occur in up to 30% of bunion patients. Eric Kuhlman, DPM of Center for Spine & Orthopedics in Denver, who performed an initial IntelliGuide Adductoplasty case commented, "This technology is going to revolutionize the way that I approach treating patients with bunion and related midfoot deformities. The virtual planning process helped me fully visualize the complex three-dimensional metatarsus adductus midfoot correction before stepping foot in the OR and the 3D-printed cut guides added a new level of intra-operative precision, efficiency, and confidence to the procedure. Just as PSI has advanced other areas of orthopedics, I expect IntelliGuide PSI to rapidly expand our understanding and treatment of these common, yet challenging foot deformities."

16:32 EST Franklin Resources raises quarterly dividend to 32c per share from 31c - The dividend is payable on January 10, 2025 to stockholders of record holding shares of common stock at the close of business on December 30, 2024.

16:30 EST Verint CFO says revenue overachievement driven by unbundled SaaS renewal revenue - Grant Highlander, Verint CFO, stated, "Q3 revenue came in at $224 million, around $14 million ahead of our guidance, representing approximately 5% year-over-year growth adjusted for last year's divestiture. Our revenue overachievement was driven by unbundled SaaS renewal revenue coming in during Q3, that we previously expected to come in Q4. In addition, gross margins expanded approximately 70bps year-over-year in Q3 driven by our mix shift to recurring revenue. We are pleased with the progress we have made year to date and we maintain our full year guidance for revenue and non-GAAP diluted EPS. We look forward to our upcoming investor day on January 14th where we will showcase our AI differentiation. Investors will hear directly from our customers on AI business outcomes and we will review our financial model, including FYE26 guidance, and our long-term model for monetizing AI."

16:29 EST Verint up 15% at $29.75 after Q3 earnings beat, affirmed FY25 guidance

16:28 EST Whitestone REIT increases quarterly dividend 9% to 13.5c per share - Whitestone REIT announced that its board of trustees has declared a monthly cash dividend of 4.5c per share on the company's common shares and operating partnership units for the first quarter of 2025. The quarterly dividend amount of 13.5c per share represents a 9% increase from the previous quarterly dividend amount.

16:25 EST Disney raises FY25 dividend payout to $1.00 per share from 75c in FY24 - The Walt Disney Company declared a cash dividend of $1.00 per share. This represents a 33% increase over the $0.75 per share paid to shareholders during fiscal year 2024. The dividend will be paid in two installments of $0.50 per share, according to the following record and payable dates: Record Dates - December 16, 2024 and June 24, 2025; Payable Dates: January 16, 2025 and July 23, 2025. "It's been a highly successful year for The Walt Disney Company, stemming from the extensive strategic work across the company to improve quality, innovation, efficiency, and value creation," said Robert A. Iger, CEO. "With the company operating from a renewed position of strength, we are pleased to increase the dividend for shareholders while continuing to invest for the future and drive sustained growth through Disney's world-class portfolio of assets."

16:24 EST OncoCyte announces publication of DetermaCNI assay data - Oncocyte announced the publication of data regarding its DetermaCNI assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations, or SCNAs, in cerebrospinal fluid. As noted in the paper, the gold standard for precise diagnostic classification of brain tumors requires a biopsy, with risks including limited sensitivity and failing to measure the diverse potential regions of the tumor. SCNAs were observed in the cerebrospinal fluid of ten out of the 12 patients with confirmed central nervous system cancers. SCNAs were not observed in any of the 11 patients with benign or unclear central nervous system lesions. The detection of SCNAs is highly specific for tumor-derived cell-free DNA. Overall, this new study demonstrates DetermaCNI's potential for providing a molecularly informed diagnosis of central nervous system cancers, mapping tumor heterogeneity, tracking tumor evolution, and surveilling tumor patients through a liquid biopsy of cerebrospinal fluid. Oncocyte believes this study validates the future clinical potential for DetermaCNI, as well as the direction of the company's research and development pipeline, which is designed to drive sustained rapid growth over the next decade. It expects to commercialize its oncology assays over the next two years.

16:21 EST Adeia announces Sharp renews multi-year worldwide license for IP portfolio - Adeia announced that Sharp Corporation, a smart TV and consumer electronics manufacturer, has agreed to renew a multi-year worldwide license for Adeia's media intellectual property, or IP, portfolio. This multi-year agreement extends the longstanding relationship between the two companies.

16:20 EST American Eagle down 13% at $17.83 after Q3 results, FY24 guidance

16:19 EST Ooma up 4% at $16.00 after Q3 results, FY25 guidance raise

16:15 EST AeroVironment down 8% at $181.10 after Q2 earnings miss

16:11 EST Five Below appoints Winnie Park as CEO - Five Below announced the appointment of Winnie Park as CEO and a member of its board of directors, effective December 16. An accomplished retail executive with a career spanning more than three decades, Park will partner closely with Kenneth Bull, who will continue as Five Below's COO. In addition, Thomas Vellios, co-founder, will continue as executive chairman, working alongside Park, Bull and the rest of the leadership team to drive the company's strategic priorities. Park will be based in Philadelphia. Park served as CEO of Forever 21 since January 2022.

16:10 EST Associated Banc-Corp announces balance sheet repositioning transactions - Associated Banc-Corp announced balance sheet repositioning transactions to accelerate the company's organic growth strategy. Pursuant to the terms of the transactions, Associated sold approximately $1.3B of investment securities and has agreed to sell approximately $0.7B in mortgage loans, primarily in single-product relationships. The sale of the mortgage loans is expected to close in Q12025. The transactions are expected to result in an after-tax loss of approximately $253M which will cause the company to report a net loss for Q4 2024. The transactions are expected to increase Associated's wholesale funding capacity by paying down FHLB advances, while also removing low-yielding assets from the books. The company has also chosen to reinvest approximately $1.5B into investment securities. CEO Andy Harmening said, "This balance sheet repositioning supports and accelerates our organic strategy by enhancing our earnings profile, boosting capital, and providing additional capacity for loan growth. As we continue to execute on our plan going forward, we feel well-positioned to attract and deepen customer relationships, take market share in key commercial markets, and enhance the value of our franchise..."

16:09 EST American Eagle reports Q3 inventory up 5% at $804M - The company states: " Inventory is healthy and well positioned for the holiday season."

16:08 EST Bluebird Bio announces 1-for-20 reverse stock split - Bluebird Bio announced that it will proceed with a 1-for-20 reverse stock split of the company's common stock following approval by both its Board of Directors and BLUE stockholders at its reconvened annual meeting held on December 4, 2024. As previously announced, the primary goal of the Reverse Stock Split is to increase the per share market price of the company's common stock to regain compliance with Nasdaq's minimum bid price requirement for continued listing. The Reverse Stock Split is expected to become effective at 5 p.m., Eastern Time, on December 12, 2024. The common stock is expected to begin trading on a split-adjusted basis when the markets open on December 13, 2024, under the existing trading symbol "BLUE". The new CUSIP number for the common stock following the Reverse Stock Split will be 09609G 209.

15:40 EST Merus' zenocutuzumab-zbco granted accelerated approval by FDA - On December 4, 2024, the Food and Drug Administration granted accelerated approval to Merus' zenocutuzumab-zbco for adults with the following: advanced, unresectable, or metastatic non-small cell lung cancer harboring a neuregulin 1 gene fusion with disease progression on or after prior systemic therapy, or; advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring a NRG1 gene fusion with disease progression on or after prior systemic therapy. This represents the first FDA approval of a systemic therapy for patients with NSCLC or pancreatic adenocarcinoma harboring an NRG1 gene fusion. Efficacy was evaluated in the eNRGy study, a multicenter, open-label, multicohort trial. The trial enrolled 64 adults with advanced or metastatic NRG1 fusion-positive NSCLC and 30 adults with advanced or metastatic NRG1 fusion-positive pancreatic adenocarcinoma who had disease progression following standard of care treatment. Identification of positive NRG1 gene fusion status was prospectively determined by next generation sequencing assays. The major efficacy outcome measures were confirmed overall response rate and duration of response, determined by blinded independent central review according to RECIST v1.1. For NSCLC, ORR was 33% and median DOR was 7.4 months. For pancreatic adenocarcinoma, ORR was 40% and the DOR range was 3.7 months to 16.6 months. In the pooled safety population, the most common adverse reactions were diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions, dyspnea, rash, constipation, vomiting, abdominal pain, and edema. The most common Grade 3 or 4 laboratory abnormalities were increased gamma-glutamyl transferase, decreased hemoglobin, decreased sodium, and decreased platelets. The prescribing information includes a Boxed Warning for embryo-fetal toxicity. The recommended zenocutuzumab-zbco dose is 750 mg, as an intravenous infusion every 2 weeks, until disease progression or unacceptable toxicity.

15:31 EST Nano Labs Ltd trading halted, volatility trading pause

15:01 EST General Dynamics board authorizes additional 10M share buyback - The board of directors of General Dynamics provided management with the authority to repurchase an additional 10M shares of the company's issued and outstanding common stock on the open market.

14:58 EST Google's new gen AI video model Veo available on Vertex AI private preview - Warren Barkley Sr. Director of Product Management at Google, blogged in part earlier: "Generative AI is leading to real business growth and transformation. Among enterprise companies with gen AI in production, 86% report an increase in revenue1, with an estimated 6% growth. That's why Google is investing in its AI technology with new models like Veo, our most advanced video generation model, and Imagen 3, our highest quality image generation model. Today, we're building on that momentum at Google Cloud by offering our customers access to these advanced generative media models on Vertex AI: Veo, now available on Vertex AI in private preview, empowers companies to effortlessly generate high-quality videos from simple text or image prompts. As the first hyperscaler to offer an image-to-video model, we're helping companies transform their existing creative assets into dynamic visuals. This groundbreaking technology unlocks new possibilities for creative expression and streamlines video production workflows. Imagen 3 will be available to all Vertex AI customers starting next week. Imagen 3 generates the most realistic and highest quality images from simple text prompts, surpassing previous versions of Imagen in detail, lighting, and artifact reduction. Businesses can seamlessly create high quality images that reflect their own brand style and logos for use in marketing, advertising, or product design. Vertex AI provides an orchestration platform that makes it simple to customize, evaluate performance, and deploy these models on our leading infrastructure. In alignment with our AI Principles, the development and deployment of Veo and Imagen 3 on Vertex AI prioritizes safety and responsibility with built-in precautions like digital watermarking, safety filters, and data governance." Reference Link

14:45 EST Signing Day Sports Inc trading halted, volatility trading pause

14:22 EST NISSAN ENERGY Charge Network adds access to 17,800 Tesla Superchargers - Nissan (NSANY) ARIYA drivers will gain access to 17,800 Tesla (TSLA) Superchargers within the NISSAN ENERGY Charge Network, or NECN, beginning on December 10. The expansion brings the total NECN to more than 100,000 public chargers in the U.S. and 25,000 in Canada. Nissan EV owners will need a Nissan-provided North American Charging Standard, or NACS, adapter kit to access Tesla Supercharger stations, now available for $235. Starting in 2025, Nissan will begin fitting EVs for the U.S. and Canadian markets with a NACS port. In addition to the newly added Tesla Supercharger network, NECN also includes access to Electrify America, the Shell (SHEL) Recharge branded network, ChargePoint (CHPT) and EVgo (EVGO) networks, in the U.S. In Canada, access includes ChargeHub, Shell Recharge branded network, FLO, Chargepoint, Circuit Electrique, BC Hydro, and the IVY branded network.

14:10 EST Cannae doesn't expect additional sales of Alight shares for 'foreseeable future' - Alight issued a statement on behalf of Cannae and Alight's Chairman of the Board William Foley, II: "Yesterday, Cannae sold 12 million shares of Alight's common stock in support of Cannae's own liquidity needs. Cannae does not generate operating income and will from time to time sell assets to generate cash for our strategic needs. This sale met that objective, and we do not have any expectations for additional sales of Alight shares for the foreseeable future. Our conviction in Alight's attractive long-term thesis and financial profile is steadfast."

13:42 EST AstraZeneca appoints Iskra Reic as Executive Vice President, International - AstraZeneca announced the appointment of Iskra Reic as Executive Vice President, International with responsibility for overall strategy and driving sustainable growth across this broad region. "This encompasses China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand," the company stated. Iskra succeeds Leon Wang who is on extended leave from the company while under investigation in China. Pascal Soriot, CEO, said: "Iskra is a highly accomplished leader with extensive international experience across multiple disciplines and a track record of improving patient access to our innovative and life-changing medicines. Her experience building partnerships will be invaluable in taking the fast-growing International region forward."

13:23 EST Meta picks Louisiana as site of $10B AI optimized data center - Meta and Louisiana Economic Development announced a $10B artificial intelligence data center in northeast Louisiana. The 4 million square foot data center, to be located in Richland Parish, will be Meta's largest in the world, the company said. Construction on the facility is expected to continue through 2030. Meta projects the data center will support at least 500 direct new jobs in Richland Parish. LED estimates the project will result in the creation of more than 1,000 indirect jobs, for a total of more than 1,500 potential new jobs in the Northeast Region. The company estimates 5,000 construction workers at peak of construction on a 2,250-acre site. Meta expects construction to continue through 2030 with site work beginning in December. The company has also committed to invest more than $200M in local infrastructure improvements, including roads and water systems.

13:05 EST PayPal says had 'nice' benefit this year from better transaction losses - Says taking "pragmatic" view towards what the company thinks loss rates will be as PayPal launches new products. Says seeing that "tick up a little bit" in Q4 with some of the new product launches.

12:32 EST PayPal says had 'very nice' Cyber 5 days in Branded - Says had "very nice" Cyber 5 days in Branded, Buy Now, Pay Later, Pay with Venmo. Says "feels really good" about that. Says "very comfortable" with previously provided guidance of mid-single growth for Q4. Comments taken from UBS Global Technology & AI Conference.

12:25 EST Shift4 drops 6% to $107.19 after Trump nominates CEO to lead NASA

12:15 EST Amazon Web Services, poolside enter multi-year agreement for generative AI - Amazon Web Services and poolside announced a multi-year agreement to make poolside's generative AI Assistant and foundation models available in Amazon Bedrock. Amazon Bedrock is a fully-managed service that offers developers access to high-performing models from leading AI companies through a single API. As a result, enterprise customers will soon be able to customize poolside's generative AI Assistant for software development with their own data, leveraging the security, privacy, and performance of AWS. As part of the agreement, poolside will also leverage AWS Trainium chips to power inference for its malibu and point foundation models, enabling optimal price performance for customers. AWS Trainium is a high-performance machine learning chip designed to reduce the time and cost of running generative AI models. AWS customers are now able to deploy poolside securely on Amazon Elastic Cloud Compute and will soon be able to so through Amazon Bedrock, relying on Amazon EC2 Trainium instances for inference.

12:02 EST Zeta Global rises 11.5% - Zeta Global is up 11.5%, or $2.76 to $26.69.

12:01 EST Pure Storage rises 23.8% - Pure Storage is up 23.8%, or $12.74 to $66.28.

12:00 EST PSQ Holdings falls -30.3% - PSQ Holdings is down -30.3%, or -$2.31 to $5.32.

11:45 EST Boeing reports U.S. Army order for three additional CH-47F Block II Chinooks - The U.S. Army ordered three additional CH-47F Block II Chinooks from Boeing, the company announced. The Lot 3 contract award, valued at $135M, is a part of the U.S. Army's ongoing modernization efforts. "This contract award follows the U.S. Army's February announcement that it is moving forward with full-rate production of the CH-47F Block II program. To date, Boeing is under contract for nine of up to 465 aircraft in the Army's current fleet. The Army has also received funding from the U.S. Congress for three aircraft as part of the next production lot and awarded Boeing a contract last year for acquisition of long lead parts. Boeing delivered the first production CH-47F Block II aircraft to the Army in June followed by the second in September," the company stated.

11:33 EST UnitedHealth asks for 'your patience and understanding' during 'difficult time'

11:33 EST UnitedHealth says working closely with NYPD

11:22 EST Toast down 4% as company presents at UBS conference

10:38 EST Cava CFO sees raising prices less than 3% in early 2025 - Cava Group CFO Tricia Tolivar made the comments while presenting at a Morgan Stanley conference.

10:01 EST BAE Systems unit awarded $6M contract from DARPA - The U.S. Defense Advanced Research Projects Agency has awarded BAE Systems' FAST Labs research and development organization a $6M contract as part of the Pipelined Reasoning of Verifiers Enabling Robust Systems program. Under the terms of the contract, BAE Systems will provide a Department of Defense-relevant system to demonstrate how formal methods tools can integrate into the development and certification process and provide assurance of correctness. The company's software engineers will also provide feedback to developers on how to ensure formal methods tools are applicable to DoD systems and how to make those tools accessible to them. Work on this program will take place at BAE Systems' facilities in Merrimack, New Hampshire; Burlington, Massachusetts; and Arlington, Virginia.

10:00 EST PSQ Holdings falls -33.3% - PSQ Holdings is down -33.3%, or -$2.54 to $5.09.

10:00 EST Salesforce rises 11.1% - Salesforce is up 11.1%, or $36.74 to $368.17.

10:00 EST Pure Storage rises 21.0% - Pure Storage is up 21.0%, or $11.27 to $64.81.

09:56 EST StoneX Group approved to operate digital asset business in Ireland - StoneX Digital International has been approved by the Central Bank of Ireland, as a Virtual Asset Service Provider to operate a digital asset business. The approval marks the latest step in the StoneX Group's continued global expansion into digital asset services for institutional clients. The StoneX Digital platform will provide execution and custody services, offering deep liquidity and flexible trading tools with multiple API integration options for seamless connectivity. These services will be integrated into the StoneX Group's suite of global prime brokerage services, complementing existing offerings across the StoneX product suite, including equities, ETFs, futures, and treasuries.

09:48 EST Salesforce rises 9.0% - Salesforce is up 9.0%, or $29.84 to $361.27.

09:48 EST Torrid falls -29.9% - Torrid is down -29.9%, or -$1.37 to $3.21.

09:47 EST Arista Networks falls -73.8% - Arista Networks is down -73.8%, or -$305.94 to $108.52.

09:38 EST Foot Locker sees year-end inventories 'approximately flat' vs. 2023 - Expects to open 27 new stores, close about 130 in 2025. Expects Q4 to be "the most meaningful margin improvement" in 2024.

09:36 EST Google's AI fund Gradient leads $13M seed round for Cake - Cake, a managed open-source AI infrastructure platform, announced it has raised $13M to bring AI to the mid-market. The recent seed round was led by Gradient, Google's early-stage AI fund, with prior pre-seed funding and participation from Primary Venture Partners. Gradient and Primary were joined in the round by Alumni Ventures, Friends & Family Capital, Correlation Ventures, Firestreak Ventures, and many individual investors.

09:35 EST Agrify Corp trading halted, volatility trading pause

09:32 EST Exicure Inc trading halted, volatility trading pause

09:28 EST AYRO partners with GLV Ventures for engineering, manufacturing - AYRO announced a partnership with GLV Ventures for the engineering and manufacturing of the Company's electric vehicle, the Vanish. The relationship will launch with the re-engineering and manufacturing of the Vanish in the United States using its original specifications.

09:26 EST Ford reports November U.S. sales up 14.3% to 166,373 vehicles - Ford reports total vehicle sales of 166,373 in November, up 14.3% from 145,559 in the same month of last year. Ford reports November electric vehicle sales of 10,821, up 20.8%, hybrid vehicle sales of 14,351, up 18.5%, and internal combustion vehicle sales of 141,201, up 13.4% from last year. Reference Link

09:26 EST Foot Locker says private label apparel business a 'bright spot'

09:24 EST GlobalFoundries receives additional $9.5M in U.S. federal funding - GlobalFoundries received an additional $9.5 million in federal funding from the U.S. government to advance the manufacturing of GF's essential gallium nitride on silicon semiconductors at its facility in Essex Junction, Vermont. The funding moves GF closer to large-scale production of GaN chips. With the ability to handle high voltages and temperatures, GaN chip technology is essential for enabling higher performance and greater energy efficiency across a range of RF and high-power control applications including automobiles, datacenter, IoT, aerospace and defense. With the award, GF will continue to add new tools, equipment and prototyping capabilities to its market-leading GaN IP portfolio and reliability testing as the company moves closer to full-scale manufacturing of its 200mm GaN chips in Vermont. GF is committed to creating a fast and efficient path for customers to realize new innovative designs and products that leverage the unique efficiency and power management benefits of GaN chip technology.

09:23 EST Foot Locker says contending with some 'recent softness' from key partner Nike - Says inventory levels with Nike "remain controlled." Says "confident" in strength of partnership with Nike.

09:20 EST DDC Enterprise appoints George Lai to Board of Directors - DDC Enterprise announced that it has appointed George Lai as an independent member of the Board of Directors. George was also appointed to serve on each Committee of the Board of Directors, including the Audit Committee where he will serve as the designated financial expert and Chair. George replaces Ms. Wei Qiao who resigned from the Board on November 30, 2024. "George brings a strong background in finance and accounting to our Board, with his CFO and Board experience with other public companies," commented Norma Chu, CEO and Chair of the Board of Directors. "George's insights and experience will be invaluable as we continue to execute on our business strategy and build a world-class multi-brand Asian consumer food company."

09:20 EST Foot Locker says Q3 results 'did not meet our expectations' - Says consumers "remain cautious" with discretionary dollars. Expects trend to continue in Q4. Expects elevated promotional activity to continue through holiday period. Does not think elevated promotional environment is structural and sees it abating over time. Expects gross margin improvement in Q4. Says "committed" to reaching long term financial targets. Says "on target" with store refresh goal. Says targeting 25% ecommerce penetration by 2026. Comments taken from Q3 earnings conference call.

09:19 EST Planet Labs expands contract with Colombia's National Police, no terms - Planet Labs PBC announced that they have expanded their contract with Colombia's National Police. Leveraging Planet's satellite data, the Colombian National Police monitors and works to eradicate illicit crop growth and harvest in near-real time. This contract specifically supports the Antinarcotics Directorate of the Colombian National Police, DIRAN. DIRAN uses aerial intelligence information, including Planet satellite data, to monitor and respond to the growth of illicit crops. With satellite data, DIRAN tracks crops, monitors their health and growth, and intervenes when they identify illegal cultivation activity.

09:15 EST Pacific Avenue completes acquisition of Flooring Business from H.B. Fuller - Pacific Avenue Capital Partners has completed the acquisition of the North American Flooring Business from H.B. Fuller Company. The Company, now operating as TEC Specialty Products, is a manufacturer of flooring repair and installation products, serving commercial and residential end markets. The Company is headquartered in Aurora, Illinois, and includes six strategically located manufacturing facilities and three warehouses across the United States. TEC's products are available through a wide network of distributors and retail locations throughout the United States and Canada. TEC Specialty Products offers its customers a comprehensive portfolio of flooring preparation and installation solutions, including adhesives, grouts, mortars, moisture mitigation products, and other specialty surface preparation and repair products. Its best-in-class brands, TEC, Parabond, Fortane, and ProSpec have a long history of reliably supporting resilient, tile, stone, wood, carpet, and other flooring applications. The acquisition of TEC Specialty Products is another example of Pacific Avenue's ability to navigate complex transactions and partner with corporate parents to quickly execute seamless carve-outs of non-core business units across a wide variety of industries. Under Pacific Avenue's stewardship, the Company will focus its efforts on further serving customer needs and executing on numerous growth prospects available in the flooring adhesives market.

09:13 EST Array Technologies, RP surpass 6GW of solar power depoloyed - ARRAY Technologies announced today that it has deployed more than 6GW of solar projects in North America through its partnership with RP Construction Services, a leading value-added distributor of solar construction materials. The ARRAY and RP teams have worked together since 2009 to serve leading solar developers and contractors across a diverse range of portfolios and projects. With a shared commitment to enabling homegrown renewable energy, ARRAY and RP have focused over the years on creating effective partnerships between employees, customers, and communities, uniting them around a goal to boost the local economy while providing clean energy.

09:12 EST EDAP TMS announces publication of results on HIFU - EDAP TMS announced the publication of the full results from the HIFI study in the prestigious, peer-reviewed journal, European Urology, which has the highest impact factor amongst scientific journals focused in urology. The study evaluated HIFU versus radical prostatectomy as a first line treatment of localized prostate cancer. The paper is entitled "Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized, HIFI Trial" and is authored by Dr. Guillaume Ploussard from Department of Urology, UROSUD, Clinique La Croix du Sud, France. Highlights: At 30 months, the adjusted STFS was higher in the HIFU arm compared with RP arm; the risk of salvage treatment is lower in the HIFU arm compared to RP. This result remains true when analyzing the subgroup with intermediate risk; International Continence Society score, a measure of stress urinary incontinence was significantly less deteriorated for HIFU; International Index of Erectile Function-5, a well validated measurement of erectile function, decreased significantly less after HIFU than after RP with a drop in difference in medians from -9, Post-procedural benefits of HIFU on both erectile function and urinary continence were demonstrated despite patients in the HIFU-treated group being an average of 9.6 years older

09:09 EST Crown Holdings to receive $300M in proceeds from sale of Eviosys to Sonoco - Following the closing of the previously announced sale of Eviosys to Sonoco Products Company (SON), Crown Holdings (CCK), will receive net cash proceeds of approximately $300M in return for its remaining equity stake of approximately 20%. Commenting on the transaction, Kevin Clothier, Crown's Senior Vice President and CFO, stated, "This completes the strategic divestiture of our European Tinplate business. We are pleased that this transaction has closed in a timely manner, and the proceeds will support our stated objective of ending the year with a net leverage ratio below 3.0x, while continuing to progress toward our longer-term target of 2.5x."

09:08 EST KULR Technology announces bitcoin treasury strategy - KULR Technology Group announced its Board of Directors has agreed to include bitcoin as a primary asset in its treasury program. With over $12 million cash on the balance sheet today and with any future cash surplus, KULR is committed to allocating up to 90% of its surplus cash to BTC. KULR's acquisition of bitcoin will be guided by market dynamics and anticipated cash flow requirements. The Company remains adaptable, with the ability to modify its approach based on evolving circumstances and strategic considerations.

09:07 EST INmune Bio, OmniScience announce partnership to accelerate Alzheimer's trial - OmniScience and INmune Bio announced a partnership to revolutionize operations for INmune Bio's global Phase 2 Alzheimer's disease, or AD, clinical trial using OmniScience's product, Vivo, a genAI-powered control tower designed specifically for centralizing and analyzing vast clinical data in real time. This solution represents an approach to clinical research, delivering immediate insights that enhance decision-making and transform traditional, time-consuming trial management. INmune Bio recently announced it completed randomization of patients for its blinded AD02 trial for patients with early AD and biomarkers of elevated neuroinflammation. The trial overenrolled with a total of 208 patients, 56% of whom were categorized as mild AD and 44% as mild cognitive impairment. INmune Bio plans to release top-line cognitive results in the second quarter of 2025.

09:06 EST Firefly Neuroscience appoints Lipschitz as Executive Chairman - Firefly Neuroscience announced the appointment of current director of the Board, Greg Lipschitz, as Executive Chairman, effective as of December 3, 2024. Lipschitz has served as Firefly's director since December 2022

09:06 EST Sage Group, Village Capital partner to empower purpose-driven startups - Sage Foundation has launched a new, three-year partnership with Atlanta-based Village Capital to support 165 impact-creating startups across Europe, UK, and the U.S. Atlanta's thriving entrepreneurial ecosystem provides the perfect opportunity for this transformative initiative, highlighting Sage's commitment to investing in the city and amplifying the voices of its dynamic business community. Sage's North American headquarters in Atlanta plays a key role in the program's mission to empower underrepresented business leaders, particularly those outside traditional tech hubs, by providing them with the mentorship, funding, and tools they need to succeed. The Sage Impact Entrepreneurship Program aims to empower 55 under-represented business leaders globally, supporting approximately 25 US businesses, each year through tailored mentoring, product support, grants, and strategic training. Together, Sage Foundation and Village Capital will champion purpose-driven startups, fostering growth for under-represented founders who are committed to making positive social, economic, and environmental impact in their communities.

09:04 EST INmune Bio, OmniScience partner to accelerate trial with Vivo - OmniScience and INmune Bio announced a pioneering partnership to revolutionize operations for INmune Bio's global Phase 2 Alzheimer's disease clinical trial using OmniScience's flagship product, Vivo, an industry-first, genAI-powered control tower designed specifically for centralizing and analyzing vast clinical data in real time. This solution represents a innovative approach to clinical research, delivering immediate insights that enhance decision-making and transform traditional, time-consuming trial management. INmune and OmniScience partnered throughout Vivo's product development and have completed the first phase of Vivo's roll-out to INmune's clinical development team. Throughout the initial rollout, significant beneficial findings include: Improved data quality through Vivo's automatic identification of data discrepancies; Enhanced visualization of COAs, supporting identification of outliers and better understanding of population distributions; Real-time answers, supporting decisions on patient enrollment criteria, even while the patient is in the clinic; Reduced reliance on time-consuming spreadsheet-based data analysis, improving collaboration between clinical and executive teams.

09:02 EST Nutriband reports record revenue for Q3, progress to NDA for AVERSA - Nutriband reported its financial results for the third quarter ended October 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA Fentanyl, with an NDA submission targeted for first half of 2025. Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary, with a focus on penetration pricing to gain a foothold with some of the industry's largest brands. The Company produced a record third quarter reporting revenue of $645,796 USD, up 50.94% YOY. Pocono manufactured products continue to roll out into prominent retail locations nationwide, including Target, Walmart, Walgreens and CVS. Progress continues on the development of AVERSA Fentanyl, with the Company maintaining its goal of submitting an NDA to the FDA in the first half of 2025. Nutriband recently updated shareholders on its development pathway, emphasizing that the NDA will primarily rely on data from a single phase 1 Human Abuse Potential study. Importantly, no Phase 2 or Phase 3 clinical trials will be required before to submission.

09:00 EST Bluebird Bio participates in CMMI Cell and Gene Therapy Access Model - bluebird bio announced it has reached an agreement with the Center for Medicare and Medicaid Innovation or CMMI to offer an outcomes-based agreement for LYFGENIA gene therapy under the Cell and Gene Therapy CGT Access Model. LYFGENIA is a one-time gene therapy approved for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events VOEs . "Ensuring timely, equitable access to gene therapy for people living with sickle cell disease insured through Medicaid has been a cornerstone of our commercial approach since approval, and we are pleased to build on this commitment by offering an outcomes-based agreement to state Medicaid agencies through the Cell and Gene Therapy Access Model," said Tom Klima, Chief Commercial & Operating Officer at bluebird bio. "We are also pleased to be able to offer fertility preservation support to eligible patients insured by Medicaid in states that opt into the Model, as we recognize these services address an important

08:57 EST LPL Financial: Frontline Investment Advisors joins LPL's broker-dealer - LPL Financial announced that financial advisors Amanda Miller, Devin Richard and Jonathan Vila, CRPC(R), of Frontline Investment Advisors have joined LPL Financial's broker-dealer, aligned with existing firm GradePoint Financial. They reported having served approximately $550 million in advisory, brokerage and retirement plan assets and join LPL from VALIC Financial Advisors, the broker-dealer for AIG Retirement Services. Based in Tampa, Fla., Miller, Richard and Vila collectively have approximately 50 years of extensive experience providing comprehensive investment advice to school employees, sheriff's office personnel and those in the medical field, all frontline workers who serve their community.

08:55 EST ECD Automotive Design launches 'Boutique' Studio - ECD Auto Design announced the launch of its new "Boutique" Studio. This innovative product offering is designed for discerning clients who dream of highly unique vehicles that transcend past the company's existing production lines. This new initiative completely redefines what's possible in the world of bespoke automotive craftsmanship. Demand for highly specialized vehicles inspired the creation of the Boutique Studio. For clients that seek vehicles outside ECD's existing production scope or desire to elevate their projects far beyond the traditional offerings, the Boutique Studio is the answer. It enables ECD to create one-of-one masterpieces that cater to these specific visions. A few examples of what you can expect might include classic Ferraris, Aston Martins, Porsches, as well as highly-customized variations of classic vehicles.

08:53 EST Hut 8 launches $250M stock repurchase program - Hut 8 announced three capital markets updates: The Company has entered into a Controlled Equity Offering Sales Agreement with the sales agents named therein pursuant to which it may offer and sell, under the Prospectus Supplement shares of its common stock, par value $0.01 per share, having an aggregate offering price of up to $500.0 million from time to time pursuant to an "at-the-market" program. The Company launched a $250.0 million stock repurchase program with respect to the Common Stock. Under the terms of the Company's Convertible Note Purchase Agreement with Coatue Tactical Solutions Lending Holdings AIV 3, Coatue has consented to the launch of the Stock Repurchase Program and elected not to require the registration of the Common Stock underlying their convertible note in connection with Hut 8's filing of a shelf registration statement on Form S-3ASR with the Securities and Exchange Commission.

08:40 EST Robinhood reports customer net deposits of over $5B in November - Ahead of its inaugural investor day, Robinhood Markets provided early insight into certain November operating data and posted an investor day presentation on the company's investor relations website. "In November, Funded Customers grew by over 400 thousand. Assets Under Custody grew to more than $190 billion - up over 15% from October 2024, up over 100% year-over-year - driven in part by customer Net Deposits of over $5 billion in November. Over the last twelve months through November, Net Deposits have totaled more than $47 billion. In November, Equity Notional Trading Volumes were over $145 billion - up over 15% from October 2024, up over 170% year-over-year, Options Contracts Traded were over 150 million - down less than 5% from October 2024, up over 50% year-over-year, and Crypto Notional Trading Volumes were over $30 billion - up over 400% from October 2024, up over 600% year-over-year. Additionally, November Margin balances were over $6.5 billion - up over 5% from October 2024, up over 80% year-over-year, and total Cash Sweep balances were over $26 billion - up over 2% from October 2024, up over 70% year-over-year. The Company plans to release its full November 2024 Operating Data next week," the company stated in a regulatory filing. Reference Link

08:39 EST Enhabit awarded damages in lawsuit against former officers, private equity firms - Encompass Health and Enhabit won their lawsuit in the Delaware Court of Chancery related to breaches of fiduciary duty by April Anthony, Luke James, and Chris Walker while they served as the senior officers at Encompass Health's former home health and hospice division, which is now Enhabit. The court awarded judgment against private equity firms Vistria Group and Nautic Partners and the home health and hospice business now known as VitalCaring Group for aiding and abetting "the egregious breaches of the duty of loyalty" by Anthony, James, and Walker. The company said, "The case was the subject of a 7-day trial in December 2023. After considering "the damning record presented at trial," the Court found that, while employed by Encompass Health, Anthony, James, and Walker usurped acquisition opportunities falling within Encompass Health's line of business, used Encompass Health's confidential information, and swayed key Encompass Health employees to join them with the promise of equity in the home health and hospice competitor that Anthony now heads. The Court noted that Anthony, James, Walker, and the private equity defendants took "great pains" to hide their misconduct, going so far as to secretly exchange diligence materials about acquisition targets for the new venture. The Court determined that VitalCaring Group, Anthony's new company, is "the result of this deceit." In addition to finding breaches of fiduciary duty by Anthony and the other two former Encompass Health officers, the Court also found that "with full awareness that their actions were wrong," Vistria and Nautic and two of their principals, David Schuppan and Christopher Corey, "drove the fiduciaries' efforts to covertly siphon opportunities, information, resources, and employees from Encompass." As a remedy for these actions, the Court of Chancery imposed a constructive trust entitling Encompass Health and Enhabit to receive 43 percent of VitalCaring Group's profits, to be paid quarterly, and 43 percent of the exit proceeds if and when VitalCaring Group is sold. The Court also awarded mitigation damages in the amount of approximately $1.62 million, and awarded attorneys' fees based on the defendants' bad faith efforts to conceal their misdeeds, which included falsifying records, deleting evidence, and "manipulating communications through lawyers." Encompass Health and Enhabit launched the litigation to protect the interests of their stockholders in the wake of the illegal and outrageous conduct of Anthony and the other former officers. Encompass Health and Enhabit believe the broader investing public will also benefit from the Delaware Court of Chancery's clear message that intentional breaches of fiduciary duty and self-dealing by corporate officers will have severe consequences. Those self-dealing officers and their co-conspirators will not be permitted to benefit themselves at the expense of a corporation's stockholders. The defendants in the case who were found liable include Walker, The Vistria Group, Vistria Fund III, Vistria senior partner David Schuppan, Nautic Partners, Nautic Partners IX, Nautic managing director Christopher Corey, and the holding company that owns VitalCaring Group."

08:38 EST Byrna Technologies announces sales from Black Friday, Cyber Monday - Byrna Technologies announced record-breaking sales from Black Friday and Cyber Monday, exceeding $2.4 million in combined revenue across Byrna.com and Amazon.com. Black Friday Highlights: Total order value of approximately $1,025,000, up 91% from approximately $537,000 in 2023. Byrna.com order value increased 70% year-over-year to $710,000, while Amazon.com order value grew 162% to approximately $315,000. Cyber Monday Highlights: Total order value of approximately $1,381,000, a 188% increase from approximately $480,000 in 2023. Byrna.com order value rose 189% to approximately $1,088,000, and Amazon order value jumped 183% to approximately $293,000.

08:36 EST Founder Group secures conditional LOA worth $68M for 100MW solar farm - Founder Group announces that it has been awarded a conditional Letter of Award, LOA, valued at approximately US$68 million, for the development of a 100-megawatt solar farm in Tanjung Malim, Malaysia. Spanning 900 acres, the solar farm will serve as a critical energy source, providing 100MW of export capacity to power an advanced AI data center in Enstek City, Malaysia. Founder Group will act as the Engineering, Procurement, and Construction, EPC, partner for this transformative project.

08:36 EST Greenidge Generation to sell South Carolina property to Data Journey for $12.1M - Greenidge Generation announced that it has entered into a definitive agreement to sell its 152-acre Spartanburg, South Carolina property to Data Journey for $12.1M in cash and an 8% profit participation interest in the property's planned data center. Greenidge purchased the Spartanburg property in 2021 for a consideration of $15M, and it included 175 acres and over 750,000 square feet of industrial buildings. In 2023, Greenidge then sold approximately 23 subdivided acres and its upgraded 44 MW mining facilities to NYDIG ABL for a total consideration of approximately $28M. The sale of the remaining 152-acre Spartanburg property will now enable Data Journey to build a new data center on the property while leveraging the site's future access to 60 MW of power that has already been secured by Greenidge. Following the completion of the property sale, Greenidge will provide support to Data Journey in the site development and buildout. The property sale and accompanying profit share structure align with Greenidge's longstanding focus on identifying and acquiring properties with access to significant low-cost power; evaluating each property's best use for bitcoin mining and data center development; maximizing power capacity; and, ultimately developing or selling to a strategic buyer, when appropriate. In alignment with this playbook, Greenidge is now evaluating other sites for similar data center buildouts and intends to partner with Data Journey on other similar sites. The property sale is expected to close in the first quarter of 2025.

08:35 EST ClearSign awarded purchase order from Rogue Combustion - ClearSign Technologies announces that it has received a purchase order from Rogue Combustion, a subsidiary of California Boiler for a boiler burner for use in their rental fleet. This purchase order came from Cal Boiler and is expected to be fabricated and shipped in the Q2 of 2025 for installation in a new rental boiler.

08:35 EST Safe Harbor, CCEF, PCCU collaborate to fund loan for Denver cannabis facility - SHF Holdings announced the closing of a $500,000 loan to PI 51st Avenue, a subsidiary of Pioneer Interests, Inc., d/b/a Natty Rems. This loan, offered under the Cannabis Resource Optimization Program and facilitated through partnerships with the Collective Clean Energy Fund and Partner Colorado Credit Union, will support energy-efficient upgrades at PI 51st Avenue's cultivation and processing facility in Denver, Colorado. The loan proceeds will allow PI 51st Avenue to invest in energy-saving lighting and other essential equipment, advancing both operational efficiency and sustainability in its cannabis production. This unique collaboration leverages resources from CCEF, a nonprofit focused on clean energy financing, and PCCU, to offer competitive loan terms to PI 51st Avenue. Through a cash collateral arrangement and an interest rate buydown agreement provided by CCEF, the loan offers significantly reduced borrowing costs to PI 51st Avenue, underscoring Safe Harbor's commitment to supporting sustainable practices within the cannabis industry.

08:34 EST Sensus Healthcare partners with Pompano Services - Sensus Healthcar has partnered with Pompano Veterinary Oncology to pioneer the use of SRT to treat companion animals across South Florida via the use of a mobile van. Pompano Veterinary Oncology is a full-service mobile veterinary medical oncology practice specializing in feline and canine oncology, with the goal of minimizing patient stress by providing home services and house calls. The purchase of this SRT-100 system allows the practice to add superficial radiotherapy to its suite of product offerings, which include chemotherapy, immunotherapy, surgery and tumor-specific electroporation therapy. The mobile van will also provide services to veterinary clinics. This is the fourth SRT system being used to treat skin tumors in animals, with two systems in use by the Colorado State University School of Veterinary Medicine in companion animals and horses, and an SRT system being used at Beit Veri College in Tel Aviv to treat tumors in cats and dogs.

08:33 EST Global Ship Lease to acquire four high-reefer ECO containerships for $274M - Global Ship Lease has contracted to purchase four high-reefer ECO-9,115 TEU containerships with an average age of 8.5 years for an aggregate purchase price of $274 million. The Newly Acquired Vessels are currently on time charters to a leading liner operator, with varied median firm durations extending for an average of 1.7 years, or up to an average of 5.0 years if all charterer's options are exercised. Assuming all options are exercised, the charters are expected to generate aggregate EBITDA of up to approximately $184 million. With these additions, the Company's fleet will comprise 72 vessels with a total capacity of 413,183 TEU. The Newly Acquired Vessels are scheduled for phased delivery between December 2024 and January 2025. The Company expects to pay for the ships with a combination of cash-on-hand and debt. The Company has received in-principle commitments for ten-year financings to be priced at SOFR + 2.50%, and benefiting from the balance of the Company's outstanding 0.64% SOFR caps. Including these financings, the Company's weighted average debt maturity would be extended to 5.3 years. We expect that the financings will contain financial and other covenants that are similar to those contained in our other financing agreements. The financings are subject to the negotiation and execution of definitive documentation and the satisfaction of certain customary closing conditions.

08:33 EST Safe & Green secures two new contracts for modular construction projects - Safe & Green announced the signing of two significant contracts, further demonstrating the Company's ability to deliver innovative and efficient solutions across diverse applications. The first contract involves the design, fabrication, and delivery of two modular containers totaling 640 square feet, equipped with a fully functional kitchen. The project is scheduled for completion by the end of January 2025. The second contract, a larger-scale initiative, encompasses up to 45 modular containers totaling 320 square feet each. These units are designed to house generator systems, meeting specialized industry needs. The first unit is expected to be completed by March 1, 2025, with the remaining containers scheduled for phased delivery thereafter.

08:32 EST Ascot Resources restarts mine development at Premier Northern Lights - Ascot Resources announced that the Company has started mobilizing people and equipment to begin the underground development of the Premier Northern Lights mine. Following the close of the recent financing on November 18th, 2024, the Company has started erecting the head cover for the PNL portal and is moving people and equipment back to the site to begin the development of PNL. Procon Mining & Tunneling Ltd, the Company's mining contractor together with Ascot personnel have started to implement the planning and mobilization to undertake the advance of the PNL portal to the Prew ore zone. On September 6th, 2024, the Company announced it was placing the operation on temporary care and maintenance, at this point the main PNL access ramp had advanced approximately 557 metres from the portal to the current face and required another 112 meters of ramp development to reach the first development headings into the Prew ore zone. The initial activities at site are to re-establish mine ventilation, undertake minor underground rehabilitation, reinstall underground infrastructure at PNL and then start the advance towards the Prew zone. The goal of the Company is to complete enough development to have both the PNL and Big Missouri mines operating when the mill is planned to restart in early Q2 of 2025.

08:31 EST Stratasys and Joe Gibbs Racing extend 20+ year deal, no terms - Stratasys and Joe Gibbs Racing JGR announced a five-year extension of their current working agreement that spans more than 20 years. The extension of its longstanding partnership with Joe Gibbs Racing, one of the most successful teams in NASCAR, cements Stratasys' role as their trusted partner in additive manufacturing."Our partnership with Stratasys has allowed us to dramatically accelerate part production and testing, which has been critical to our success," said Mark Bringle, Managing Director, Technical Partnerships, Joe Gibbs Racing. "We're excited to build on this collaboration and look forward to what we can achieve together over the next five years. Stratasys has been an invaluable partner for over two decades, providing us with cutting-edge 3D printing solutions that drive our competitive edge on the track. This new

08:26 EST Amentum Awarded DOE West Valley Deactivation & Demolition Contract - Amentum announced that West Valley Cleanup Alliance a BWXT Technical Services Group-led joint venture that includes Jacobs Technology, an Amentum company, and Geosyntec Consultants has been awarded the West Valley Project Phase 1B Deactivation & Demolition contract. Amentum will bring advanced environmental capabilities to safely clean up the West Valley Demonstration Project WVDP in western New York state. "With our extensive experience bringing advanced technical solutions such as UAV, robotics, sensors, telematics, and other digital tools to safely decommission nuclear facilities, we are pleased to be selected as the Department of Energy's partner," said Steve Arnette, Amentum's Chief Operating Officer. "Amentum and our partners have a successful track record addressing deactivation and decommissioning challenges and we look forward to partnering with our DOE client, regulators, and community stakeholders to further advance the cleanup mission at the West Valley Demonstration Project." The U.S. Department of Energy DOE single-award IDIQ contract has a maximum value of up to $3B over a 10-year ordering period. Performance of task orders issued before the end of the contract ordering period shall not exceed five years beyond the end of the contract ordering period. The West Valley Demonstration Project is an approximate 150-acre area located 35 miles south of Buffalo, New York. The site is owned by the New York State Energy Research and Development Authority and is home to the only commercial spent nuclear fuel reprocessing facility to operate in the United States. Amentum and its legacy companies have supported the DOE's office of Environmental Management WVDP cleanup program since 1982.

08:23 EST Campbell's says 'committed' to returning cash to shareholders

08:22 EST Campbell's expects stronger operating earnings growth, margin in 2H

08:21 EST TotalEnergies to acquire VSB for EUR 1.57B, sell 50% portfolio in some projects - TotalEnergies (TTE) announces the signing of an agreement with Swiss asset manager Partners Group for the acquisition of VSB Group, a Germany based renewable energy project developer for a consideration of EUR 1.57B. This transaction will strengthen TotalEnergies Integrated Power value chain in Germany, which represents half of VSB's portfolio. On another side in line with its Integrated Power business model, TotalEnergies has signed an agreement with funds managed by Apollo (APO) for the sale of 50% of a portfolio of 2 GW solar and battery energy storage systems, BESS, projects located in Texas. This transaction will provide $800M cash to TotalEnergies, $550M equity from Apollo and $250M shareholder loan refinancing.

08:18 EST 180 Life Sciences appoints Stephen Shoemaker to board of directors - 180 Life Sciences announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024. At WIN Group, where he served as CEO, he redefined the company's strategic direction, leading to significant growth in user engagement and financial performance. As CEO of Engine Media Holdings, he integrated multiple acquisitions, creating the first publicly-traded pure-play eSports company, listed on both the TSXV and Nasdaq Capital Market. In conjunction with this appointment, the Company announces that Omar Jimenez, 180's CFO, is stepping down from the Board of Directors to focus exclusively on his role as CFO.

08:17 EST Signal Gold files early warning release on disposal of Magna Terra shares - Signal Gold announces that it has disposed of ownership and control of 15,035,795 common shares of Magna Terra Minerals on December 3, 2024 through the facilities of Chi-x and Omega alternative markets. The Subject Shares represented approximately 18.1 % of all the issued and outstanding common shares of the Company as of December 3, 2024. As a result of the disposition of the Subject Shares, the Acquiror no longer holds any securities of the Company.The aggregate consideration received for the Subject Shares was $225,536.93, based on the sale of 15,035,795 Subject Shares at an average price of $0.015 per Subject Share. The holdings of securities of the Corporation by the Acquiror were managed for investment purposes. The Acquiror does not intend to acquire additional securities of the Corporation at this time.

08:16 EST Campbell's says competitive environment remains 'constructive' - Sees improving environment through balance of FY25. Comments taken from Q1 earnings conference call.

08:13 EST Auddia announces acceleration of user retention momentum into Q4 - Auddia has accelerated its 30-day user retention metrics to 21% in October, far exceeding its internal goal of 10% and continuing its upward momentum from the summer as a result of its new product and marketing initiatives. Auddia has focused on growing its user retention for the past year through a steady cadence of product enhancements that included new ad-free podcast listening experiences, integrations into Apple CarPlay and Android Auto, as well as numerous UX improvements under its faidr 3.1 initiative. These efforts have resulted in compelling gains in 30-day retention, growing from 5% to over 20% over the past year. As the Company continues to add value to the listening experience, it expects continued success with retention, which serves as the baseline for conversions to the paid subscription tier. Executions to optimize the conversion of subscriptions from the free tier are starting this month with updated subscription conversion metrics and new revenue expected to be reported in the first quarter of 2025.

08:12 EST Cabot introduces three-year financial targets at investor day - Cabot hosts its 2024 investor day in Boston, Massachusetts. Sean Keohane, president and CEO, and other members of Cabot's executive management team, will provide a review of the company's strategic vision and financial targets for the next three years. Cabot is introducing the following three-year financial targets: adjusted EPS CAGR of 7%-10% from FY24 through fiscal 2027; adjusted EBITDA of $0.9B-$1B by FY27. "As we build on this momentum, Cabot remains committed to creating long-term value for our shareholders through earnings growth, robust cash flow generation, and disciplined capital allocation. With our global scale, operational and commercial excellence, and commitment to sustainability, we are confident in our ability to achieve our next set of strategic objectives, including an Adjusted EPS CAGR of 7-10% over the next 3 years and Adjusted EBITDA of $0.9-$1 billion by fiscal 2027. In addition, we remain committed to maintaining an investment-grade credit rating, executing on our growth priorities and returning robust levels of cash to shareholders through disciplined capital allocation," said Sean Keohane, president and CEO.

08:11 EST Foresight Autonomous signs strategic agreement with 7meerkat - Foresight Autonomous announced the signing of a three-way multi-phase strategic cooperation agreement with 7meerkat, a South Korean company providing next generation parking and city management systems, and KONEC, a leading South Korean Tier-One automotive supplier. The parties will collaborate to develop and commercialize artificial intelligence-powered smart parking and city management solutions using Foresight's advanced 3D perception technology. The agreement follows the successful completion of a proof-of-concept project that assessed the performance of Foresight's technology in detecting vehicles and pedestrians in parking lots in harsh weather and low-light conditions.

08:10 EST Solid Biosciences announces collaboration with Mayo Clinic - Solid Biosciences announced a collaboration with Mayo Clinic seeking to advance a cutting-edge AAV gene therapy platform for the development of next-generation therapies to treat sudden cardiac death-predisposing genetic cardiomyopathies and channelopathies with high unmet medical need and significant patient populations. Under the terms of the agreement, Mayo Clinic's Windland Smith Rice Sudden Death Genomics Laboratory will provide Solid with an exclusive license to their Suppression and Replacement gene therapy platform. The collaboration will also provide Solid with an exclusive license to develop and commercialize six cardiac gene therapy programs developed using Mayo Clinic's "Sup-Rep" platform. These programs will use Solid's next-generation AAV capsids, including AAV-SLB101, and advanced manufacturing capabilities to suppress and replace genes implicated in potentially life-threatening genetic heart diseases. Mayo Clinic will be responsible for research and development efforts for each cardiac gene therapy candidate up to IND-enabling studies, at which point, Solid will have the option to pursue continued development and commercialization of each licensed program.

08:09 EST Venu Holding welcomes Terri Liebler as Chief Marketing Officer - Venu Holding (VENU) announces Terri Liebler as its new Chief Marketing Officer. With 30 years of experience in the sports and entertainment industry, Liebler has significant experience with strategic growth and profitability enhancement, and a track record of driving success through visionary leadership.VENU Chief Marketing Officer Terri Liebler Liebler, is a widely respected leader in the hospitality and entertainment industries. Before joining VENU, she held the role of Senior Vice President in the Media and Sponsorship Division at Live Nation Entertainment (LYV), where she led innovative opportunity development, strategic planning, and streamlined operational sales processes across the division. Her 22-year tenure at Live Nation included pioneering work on U.S. and international venue and festival platforms, while also facilitating critical relationships with Live Nation's external partner organizations.

08:08 EST Ingram Micro announces multi-year SCA with Amazon Web Services - Ingram Micro (INGM) announced a multi-year strategic collaboration agreement, or SCA, with Amazon Web Services (AMZN), or AWS, designed to drive more business to and through the global IT channel via Ingram Micro's digital twin Xvantage.

08:07 EST Elevai Labs subsidiary achieved record-breaking month in sales for 2024 - Elevai Labs announces that its wholly owned subsidiary, Elevai Skincare, has achieved a record-breaking month in sales for 2024, marking a significant milestone for the Company. This achievement underscores the success of transformational restructuring efforts led by Elevai Labs' new executive team and the adoption of a performance-driven culture. Preliminary unaudited sales data for Elevai Skincare for November 2024 reflects revenue of $300K significantly higher than monthly figures earlier in the year.

08:07 EST EVgo,GM charging deal exceeds 2,000 public fast charging stalls in the U.S. - EVgo (EVGO) and General Motors (GM) have surpassed 2,000 public fast charging stalls opened through their ongoing metropolitan charging collaboration. To date, EVgo and GM have built fast charging stalls in more than 390 locations in 45 metropolitan markets across 32 states as part of a longstanding collaboration to broaden access to public charging in amenity-rich locations, such as grocery stores, retail centers and city centers, while also serving customers who are unable to charge at home or work, such as renters and those living in multifamily dwellings. GM has accelerated the buildout of our nationwide network, inspiring range confidence for today's EV drivers and the drivers we will welcome to the EVgo network in the years to come." "Our collaboration with EVgo underscores our dedication to providing EV drivers with the best possible experience by expanding fast charging infrastructure across the country," said Wade Sheffer, Vice President, GM Energy. "We look forward to continuing to offer premium charging experiences for years to come." /

08:06 EST Ashford Hospitality to sell Courtyard Boston Downtown for $123M - Ashford Hospitality Trust announced that it has signed a definitive agreement to sell the 315-room Courtyard Boston Downtown located in Boston, Massachusetts for $123.0M, or $390,500 per key. The sale is expected to be completed in January 2025 and is subject to normal closing conditions. The Company provides no assurances that the sale will be completed on these terms or at all. When adjusted for the Company's anticipated capital expenditures, the sale price represents a 5.9% capitalization rate on net operating income for the trailing twelve months ended September 30, or 14.3x Hotel EBITDA for the same time period. Excluding the anticipated capital spend, the sale price represents a 6.9% capitalization rate on net operating income for the trailing twelve months ended September 30, or 12.3x Hotel EBITDA for the same time period.

08:05 EST Dare Bioscience received payment of $2.5M under grant agreement - Dare Bioscience announced it received a payment of $2.5M as the latest installment under a grant agreement to advance the development of Dare's investigational contraceptive DARE-LARC1 through nonclinical proof of principle studies and other IND-enabling work to allow for the submission of an Investigational New Drug, IND, application with the FDA, approval of which will be required to commence testing in humans. Under the terms of the grant agreement, Dare may receive a total of up to approximately $49 million to support nonclinical development of DARE-LARC1. To date, Dare has received payments totaling approximately $31.8 million. Additional payments are conditioned on the program meeting specified development and reporting milestones.

08:04 EST ARS Pharmaceuticals announces planned launch of neffyinSchools - ARS Pharmaceuticals announced that it will be launching the neffyinSchools Program in January 2025. The program will provide eligible public and private K-12 schools in the U.S. the opportunity to receive two cartons of neffy 2mg for use in emergency situations at no cost to the school. neffy 2mg was recently approved for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. Participating schools will be eligible to receive replacement doses when the product is used or expires.

08:03 EST X4 Pharmaceuticals to present on Phase 3 study of Mavorixafor - X4 Pharmaceuticals announced its upcoming presentations at the 66th American Society of Hematology Annual Meeting and Exposition, including a trial-in-progress poster on the ongoing pivotal Phase 3 clinical trial exploring the use of mavorixafor, an oral CXCR4 antagonist, for the treatment of people with chronic neutropenia. The meeting will take place December 7-10, 2024, in San Diego, CA. "We're pleased to be sharing details of our ongoing Phase 3 clinical trial at ASH as we continue to recruit patients and activate study sites across the globe. The initiation of this trial was a significant milestone for the chronic neutropenia community that - unfortunately - hasn't seen any treatment innovation in nearly 30 years," said Paula Ragan, CEO. "We look forward to connecting with clinicians at the ASH meeting and sharing more about our vision for mavorixafor as an oral option for the treatment of CN that could potentially reduce or replace the use of injectable G-CSF." The Phase 3 4WARD trial is evaluating the efficacy, safety, and tolerability of oral, once-daily mavorixafor in people with congenital, acquired primary autoimmune or acquired primary idiopathic CN who are experiencing recurrent and/or serious infections. The 52-week trial is a randomized, double-blind, placebo-controlled, multicenter study aiming to enroll 150 participants across 90 to 110 sites in 20 to 25 countries. X4 will also be hosting a booth at the conference to share information about the ongoing 4WARD clinical trial. Additionally, in an oral presentation at the meeting, the company will present preclinical data on the potential for CXCR4 antagonism to correct peripheral blood neutropenia and bone marrow neutrophil accumulation caused by a loss-of-function in the CXCR2 pathway.

08:03 EST Windtree Therapeutics announces partnership with New Growth Advisors - Windtree Therapeutics announced that it has engaged New Growth Advisors, NGA, a leading life sciences consulting firm chosen by companies seeking discreet, conflict-free, and knowledgeable advice on complex M&A, asset sale, research, capital markets, and licensing transactions, as its strategic advisor to lead a process in respect of Windtree's cardiovascular portfolio, including a potential out-licensing transaction or asset sale. NGA has advised on transactions with an aggregate value approaching $400 million from 2023 through 2024.

07:53 EST Cross Country Healthcare to be acquired by Aya Healthcare for $18.61 per share - Aya Healthcare and Cross Country Healthcare announced that they have entered into a definitive agreement whereby Aya will acquire Cross Country for $18.61 per share in cash in a transaction valued at approximately $615M. The all-cash transaction represents a premium of 67% to Cross Country's closing price on December 3 and a premium of 68% to the volume-weighted average trading price for the 30-day trading period ended December 3. Following completion of the transaction, and to ensure a transition, Martins will continue to serve as president and CEO of Cross Country as part of Aya. Completion of the transaction is expected in the first half of 2025, subject to the approval of Cross Country stockholders and the satisfaction of other customary closing conditions, including regulatory approvals. The transaction is not subject to a financing condition. The Cross Country board of directors unanimously approved the merger agreement and intends to recommend that Cross Country stockholders vote in favor of it at a special meeting of stockholders, to be scheduled as soon as practicable. Upon completion of the transaction, Cross Country will become a private company and its common stock will no longer trade on the Nasdaq. Aya expects to maintain a significant presence in Boca Raton, Florida.

07:47 EST Trisura Group announces normal course issuer bid - Trisura Group announced the Toronto Stock Exchange has accepted a notice filed by Trisura Group Ltd. of its intention to make a Normal Course Issuer Bid to be transacted through the facilities of the TSX and/or alternative trading systems. The notice provides that Trisura Group may, during the 12-month period commencing December 6, 2024 and ending December 5, 2025, purchase up to 1,433,371 common shares in total, representing approximately 3% of Trisura Group's issued and outstanding common shares. As at November 22, 2024, Trisura Group had 47,779,021 common shares issued and outstanding. Under the NCIB, Trisura Group may purchase up to 17,689 common shares on the TSX during any trading day, which represents 25% of the average daily trading volume of 70,758 common shares on the TSX for the six months ended November 30, 2024. The purchase of Trisura Group common shares is intended to offset dilution resulting from the issuance of common shares pursuant to Trisura Group's equity incentive programs. The establishment of the NCIB also provides Trisura with the flexibility to acquire common shares from time to time as an effective means of returning capital to its shareholders.

07:40 EST Amesite's NurseMagic meets HIPAA requirements for enterprise customers - Amesite announced the company's app, NurseMagic, has executed infrastructure and business practices to meet the requirements of the Health Insurance Portability and Accountability Act. Amesite's proprietary AI-powered platform enables an outstanding user experience, providing on-the-job assistance to care provider management and frontline staff. Over 27 different professions are currently using the app, following a period of rapid growth since its public launch just six months ago.

07:38 EST Euro Manganese announces amendment to funding package with Orion - Euro Manganese has amended the $100 million funding package with OMRF, which is managed by the Orion Resource Partners. The Funding Package, originally announced on November 28, 2023, supports the development of the Chvaletice Manganese Project in the Czech Republic, and consists of a $50 million Convertible Loan Royalty Agreement, of which $20 million has been advanced to the Company, and a $50 million royalty on Project revenues, subject to the Company meeting certain milestones related to the development of the Project. The current CLRA requires the Company pay cash interest to Orion. Based on the amendment to the CLRA, interest amounts accruing with effect from January 1, 2025 will be deferred and added to the principal balance of the convertible loan, conserving $2.8 million per annum of cash for the advancement of the Project. The CLRA amendment interest rate is 14.00%. The dates for certain milestone obligations under the amendments to the CLRA and Royalty Agreement have been extended to allow for advancement of the Project. Euro Manganese has been granted the right to repay the convertible loan at par at any time prior to conversion, including all accrued and unpaid interest, and may cancel the second tranche of the CLRA without penalty. Euro Manganese has been granted the right to terminate the Royalty Financing at any time prior to the satisfaction of the conditions precedent for the Royalty Financing for a fee of $1 million, provided that the outstanding convertible loan amounts under the CLRA have been repaid in full at such time. Euro Manganese will, subject to TSX Venture Exchange approval, and in the event certain conditions precedent are met with respect to future equity fundraising activities, issue warrants to purchase common shares of the Company to Orion.

07:36 EST SRM Entertainment's Amazon sales surge over 400% - SRM Entertainment (SRM) announced that its online sales on Amazon (AMZN) have surged by over 417% since September. This exceptional growth is driven by strong customer demand for the company's high-margin products and is expected to have a significant positive impact on its financial performance.

07:35 EST Rectitude Holdings enters MOU with Nanjing Starship - Rectitude announced it has entered into a memorandum of understanding, MOU, with Nanjing Starship Intelligent Storage Technology Co. to provide its All-in-one Intelligence Micro-grid System, a next-generation energy storage solution with the potential to transform how industries manage power. "This partnership with Nanjing Starship serves as a milestone in our long-term strategic goals to provide innovative solutions to enhance workplace safety. As we continue to innovate in our field, we are focused on providing the highest quality products to our partners and customers. The micro-grid system is transforming energy management by offering scalable, flexible, and efficient power solutions," said Jian Zhang, Chairman, Chief Executive Officer, and Executive Director at Rectitude. "This innovation sets a new benchmark in energy storage, providing potential revenue growth, expanding product range, and ultimately strengthening our leading position in the industry. We are excited to be partnering with such a high-profile company, and believe this is just the starting point of what is to come in the future."

07:33 EST Amylyx announces design of LUCIDITY clinical trial - Amylyx announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1, receptor antagonist, for the treatment of post-bariatric hypoglycemia, or PBH. LUCIDITY is designed to evaluate the FDA-agreed upon primary outcome of reduction in hypoglycemia events and to have similar inclusion and exclusion criteria to the previous Phase 2 trials of avexitide in PBH. Amylyx expects that the first study participant will be dosed in the first quarter of 2025, followed by expected completion of recruitment in 2025, and anticipates topline data in 2026. LUCIDITY will be a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with PBH following Roux-en-Y gastric bypass surgery. The Phase 3 trial will be conducted at approximately 20 sites in the U.S. Approximately 75 participants will be randomized 3:2 to receive either 90 mg of avexitide subcutaneously once daily or placebo. The trial will include a three-week run-in period and a 16-week double-blind treatment period. Participants who complete the double-blind period of the planned study will be eligible to enter an open-label extension period with a duration of 32 weeks. The primary efficacy objective of LUCIDITY will evaluate the reduction in the composite of Level 2 and Level 3 hypoglycemia events through Week 16. Safety and tolerability will also be evaluated. Avexitide was generally well tolerated, with a favorable safety profile replicated across the clinical trials. Amylyx will present the trial design at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease in Los Angeles on December 12-14.

07:33 EST Roku jumps 5% to $79.43 after Needham predicts 2025 takeover - The shares are up $3.74 to $79.43 in pre-market trading after Needham predicted Roku will be sold for a "big premium" in 2025.

07:33 EST Zimmer announces FDA clearance of Persona SoluTion Porous Plasma Spray Femur - Zimmer Biomet Holdings announced FDA clearance of Persona SoluTion Porous Plasma Spray Femur, a total knee implant component offering an alternative for patients with sensitivities to bone cement and/or metal. The Persona SoluTion PPS Femur features a porous coating for cementless fixation and leverages a proprietary surface treatment designed to enhance wear performance. Hypersensitivity to metal is a challenge for a certain patient population associated with a traditional cemented total knee replacement, or TKR, with an implant made of cobalt-chrome, Co-Cr-Mo, alloy. When exposed to certain metals, people with these hypersensitivities can experience an inflammatory response, pain and implant loosening that can require a revision TKR.4 Persona SoluTion PPS Femur offers cementless fixation with its clinically proven PPS coating that provides initial scratch fit stability and supports biologic fixation through bony ongrowth.3-12 When combined with Persona OsseoTi tibia and Vivacit-E Highly Crosslinked Polyethylene, or HXLPE, the total knee implant is designed to minimize the most common metal sensitizers, or nickel, cobalt and chromium, likely to elicit an immune response and is made of a proprietary Tivanium, or Ti-6Al-4V, alloy with over 17 years of clinical use. The Tivanium alloy is treated with the Ti-Nidium Surface Hardening Process and is compatible with Vivacit-E HXLPE articular surfaces. The Persona Solution PPS femur coupled with a Vivacit-E bearing demonstrates similar wear performance as compared to Persona cobalt chromium alloy femur coupled with a Vivacit-E bearing. Persona SoluTion PPS Femur will be commercially available in the U.S. in Q1 2025.

07:09 EST Altair and Auburn University to work on $1.25M AFWERX Phase II STTR contract - Altair will work together with Auburn University's Samuel Ginn College of Engineering on a $1.25M AFWERX Phase II STTR contract. The two organizations will develop analytical models for cyclonic flows, construct computational models, and study the stability of different vortex engines to address the challenges facing public and private sector aerospace organizations. Within the contract, Altair is assuming the previous role of Research in Flight, which was founded in 2013 and won a series of development contracts and grants over a 10-year span. Altair acquired Research in Flight in April 2024 and its technology is now known as Altair FlightStream, part of the Altair HyperWorks platform. Within the project, the Auburn University team will use FlightStream to identify optimal conditions within vortex engines. FlightStream will help the team predict cyclonic flow performance and acoustic signature characteristics at a fraction of the time compared to previous methods. These models will enable users to rapidly predict the stability performance of thrust engines earlier in the design cycle over a range of operating conditions. The contract is awarded by AFWERX. AFWERX is the innovation arm of the United States Department of the Air Force, or DAF, that harnesses cutting-edge American ingenuity from small businesses and startups to address the most pressing challenges of the DAF.

07:08 EST Mangoceuticals initiates investigation into potential stock manipulation - Mangoceuticals has launched an investigation into potential stock manipulation related to and following its recent reverse stock split, which was effective as of October 16, 2024. This decision follows a comprehensive review of highly irregular trading patterns and an unprecedented increase in the number of shareholder accounts, factors that collectively raise concerns about potential stock manipulation. This investigation also follows a recent request the Company received from the Depository Trust Company Corporation whereby DTC requested from MangoRx's transfer agent delivery of an additional 213,327 shares of MangoRx's common stock reflecting the "round-up" of fractional shares outstanding on a post-reverse split basis. This requested amount represents approximately 9% of MangoRx's total issued and outstanding shares based on a total of approximately 2.4 million shares outstanding on a post-reverse split basis, before such rounding. Prior to the reverse split, MangoRx had approximately 5,000 total shareholders. However, the substantial share request suggests an unprecedented increase in shareholder accounts, potentially indicating an increase of more than 200,000 accounts post-split - a scenario that warrants an additional investigation. To facilitate this unprecedented increase in shareholder accounts, MangoRx observed a nearly impossible pattern of trading activity, including tens of thousands of high-frequency single-share transactions leading up to and immediately following the effective date of the reverse split. These transactions, unique in their volume and frequency by the Company's record, have contributed to suspicions of possible manipulation in a broader scheme. To ensure the integrity of MangoRx's shareholder base, Jacob Cohen, the Company's Founder and CEO, has denied DTC's request in issuing and delivering these additional shares until a thorough investigation can be completed.

07:07 EST TransAlta closes acqusition of Heartland Generation - TransAlta Corporation announced that it has completed its acquisition of Heartland Generation Ltd. and Alberta Power from Energy Capital Partners, ECP. The acquisition, which includes Heartland's entire business operations in Alberta and British Columbia, was completed for an aggregate purchase price of $542 million, reduced by approximately $95 million to reflect the economic benefit of the Heartland business arising since October 31, 2023, resulting in a net cash payment of $215 million before working capital adjustments.

07:06 EST Tilray's Hop Valley announces new partnership with Portland Trail Blazers - Hop Valley Brewing,, a subsidiary of Tilray Brands, announces its new partnership with the Portland Trail Blazers and the opening of the Hop Valley Brewing Hop Box bar inside Moda Center. This innovative and vibrant new bar is set to enhance the fan experience at Portland's premier sports and entertainment venue.

07:05 EST Can-Fite announces 8 year survival for patient in Phase 2 Liver Cancer study - Can-Fite BioPharma announced that a patient currently treated with Namodenoson in a compassionate use program in Can-Fite's Phase II Liver Cancer Study has an overall survival time of 8 years with a complete response. The patient, who suffered from advanced liver cancer was enrolled in the former Can-Fite Phase II study, continue to be treated with Namodenoson, and has now an overall survival of 8 years, with disappearance of ascites, normal liver function, good quality of life and is defined as a long term complete response.

07:05 EST Air Industries gets $4M follow-on contract for F-35 arresting gear components - Air Industries Group announced that it has secured a follow-on contract valued at approximately $4M for arresting gear components to be used on the F-35 Lightning II fighter aircraft. The contract originated in a European partner nation of the F-35 program. Production of the arresting gear components is expected to begin in the first half of 2025, with the contract scheduled for completion by year end 2025. This agreement demonstrates Air Industries Group's commitment to supporting global defense initiatives and solidifying its role as a trusted supplier in the aerospace and defense sector. Lou Melluzzo, Chief Executive Officer of Air Industries Group commented: "The initial contract for these products was awarded in 2023, representing our first experience with this new customer. The current order affirms the mutual trust that we have established during the period of performance, and underscores our strategic objective to expand international sales, and to continue our strong support of the F-35 program."

07:04 EST Stoke Therapeutics zorevunersen receives Breakthrough Therapy Designation - Stoke Therapeutics announced that it has received Breakthrough Therapy Designation from the FDA for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation, not associated with gain-of-function, in the SCN1A gene. Zorevunersen is being developed as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.

07:04 EST Alta Global reports 'surge in demand' for Warrior Training Programs - Alta Global Group reported a strong start for its partnership with UFC Gym Group. Alta's innovative 20-week Warrior Training Program, which transforms beginners into combat athletes, has seen a surge in demand, with sign-ups in the past few weeks, significantly outpacing initial projections. Leveraging its social and ambassadorial reach, and mobile marketing platform, Alta has been reaching more MMA fans and enhancing customer acquisition. Developed by Alta and exclusively offered in partnership with UFC Gym, the 20-Week Warrior Program is an unprecedented opportunity for UFC fans, blending world-class coaching with the thrill of competing in a professionally organized MMA fight finale. The finale event offers participants the chance to step into the Octagon and emulate their UFC heroes, fighting in front of cheering friends, family, and fans-a once-in-a-lifetime experience. At $1,500 per participant, the 20-week program delivers unmatched value for a premium experience. UFC Gym locations in Costa Mesa and Huntington Beach are reporting strong enrolment numbers, driven by the leadership of elite trainers such as current UFC fighter Cub Swanson and MMA veteran Jamie Fletcher, with more gyms across Southern California preparing to roll out the program in early 2025.

07:03 EST Gogo announces senior leadership appointments - In connection with the completion of the combination with Satcom Direct, Chris Moore, President of SD, has been appointed Gogo's Chief Executive Officer and will lead the combined company, bringing years of satellite and telecommunications experience and success to his new role. He succeeds Thorne, who transitions to Executive Chair of the Gogo Board of Directors. In addition, Zachary Cotner, CFO of SD, has been appointed CFO of the combined company, succeeding Jessi Betjemann. Mike Begler, who previously served as Senior Vice President of Gogo Production Operations, has been appointed Executive Vice President, COO of the combined company.

07:03 EST Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir - Atea Pharmaceuticals announced that the Company's Phase 2 study of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for treatment of hepatitis C virus met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment. Primary endpoint results demonstrated a 98% SVR12 rate in the per-protocol treatment adherent patient population after eight weeks of treatment with a regimen of bemnifosbuvir and ruzasvir. The efficacy evaluable patient population, which included 17% treatment non-adherent patients, achieved a 95% SVR12 rate demonstrating the robust potency and forgiveness of the regimen. The regimen was generally safe and well-tolerated with no drug-related serious adverse events or treatment discontinuations. An accompanying slide deck with the topline Phase 2 results is available on Atea's website here. Full data for the Phase 2 study are anticipated to be presented at a scientific meeting during the first half of 2025.

06:59 EST Eli Lilly announces topline results from SURMOUNT-5 trial - Eli Lilly announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound provided a 47% greater relative weight loss compared to Wegovy. On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. At 72 weeks, Zepbound beat Wegovy on both the primary endpoint and all five key secondary endpoints in this trial of adults living with obesity or overweight with at least one weight-related medical problem and without diabetes. In addition, in a key secondary endpoint, 31.6% of people taking Zepbound achieved at least 25% body weight loss compared to 16.1% of those taking Wegovy. The overall safety profile of Zepbound in SURMOUNT-5 was similar to previously reported SURMOUNT trials. The most commonly reported adverse events in SURMOUNT-5 for both Zepbound and Wegovy were gastrointestinal-related and were generally mild to moderate in severity. Lilly will continue to evaluate the SURMOUNT-5 results, which will be published in a peer-reviewed journal and presented at a medical meeting next year. Tirzepatide is commercialized for adults with obesity or with overweight who also have weight-related medical problems as Zepbound in the U.S. and Mounjaro in some global markets outside the U.S. Tirzepatide is also commercialized as Mounjaro for adults with type 2 diabetes in the U.S. Semaglutide is commercialized as Wegovy for people living with obesity or for adults with overweight who also have weight-related medical problems and Ozempic for people with type 2 diabetes.

06:47 EST Vincerx Pharma announces workforce reduction of 55%, cost-control measures - Vincerx Pharma announced plans to implement cost-controls and explore strategic alternatives to support advancing the Phase 1 study of VIP943, the company's novel CD123-targeted antibody-drug conjugate developed with the company's next-generation VersAptx platform. "We believe VIP943 is a highly differentiated and valuable asset, and we remain fully committed to advancing this program," said Ahmed Hamdy, M.D., Chief Executive Officer. "As we shared in October, the Phase 1 dose-escalation study of VIP943 has demonstrated encouraging safety, efficacy, and tolerability. Of nine evaluable patients, one patient whose acute myeloid leukemia relapsed post-transplant achieved a CRi and one patient with higher-risk myelodysplastic syndrome achieved a CRL. Notably, since October, the patient with CRi has continued to improve, with their most recent bone marrow results showing only 1% cancer cells. This patient has now been on the study for seven months and counting. Monotherapy responses in post-transplant patients are rare, so we believe this type of response highlights the potential of VIP943 in this challenging population and supports the next-generation technology of our VersAptx platform." Dr. Hamdy continued, "Our immediate focus is to give the program time to generate more data, with results from additional cohorts expected by early Q1 2025. To support this, we are implementing significant cost-cutting measures to focus resources on VIP943's advancement. Additionally, we will begin exploring strategic alternatives to complement our ongoing fundraising efforts, with the goal of maximizing the value of the VIP943 program and our VersAptx platform." As part of its review of potential strategic alternatives, Vincerx will consider options such as out-licensing, merger and acquisition opportunities, including reverse mergers, sales of assets and technologies, and other transactions. To streamline operations and focus resources, Vincerx will implement a significant reduction in force of approximately 55%. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or as to the timing of any such agreements or transactions. The company is in the process of engaging a financial advisor to assist in the strategic review process. Vincerx has not set a timetable for completion of the evaluation process and does not intend to disclose further developments or guidance on the status of its exploration of strategic alternatives unless and until it is determined that further disclosure is appropriate or necessary. As of October 31, the company had approximately $8.4M in cash, cash equivalents, and marketable securities.

06:41 EST NexGen Energy awarded uranium sales deals with U.S. nuclear utility companies - NexGen Energy announced it has been awarded the first uranium sales agreements with multiple U.S. nuclear utility companies. These inaugural awards all incorporate market-related pricing mechanisms at the time of delivery. They reflect NexGen's long stated focus of maximizing leverage to future uranium prices and the Company's positioning as a new reliable Western World source of nuclear fuel incorporating the highest standards of technical, environmental and social inclusion from the tier one jurisdiction of Saskatchewan Canada.

06:36 EST Dollar Tree sees Q4 SSS growth in the low-single-digits - Sees Q4 comparable store net sales growth in the low-single-digits for the enterprise and both the Dollar Tree and Family Dollar segments.

06:35 EST General Motors sees more than $5.3B in charges related to China business - In a regulatory filing, GM stated: "General Motors Company owns an equity interest in SAIC General Motors Corporation Limited, or 'SGM,' a 50-50 joint venture with SAIC Motor Corp., and an equity interest in SAIC-GMAC Automotive Finance Company Limited. SGM conducts automotive operations in China through various other joint ventures with GM. On December 2, 2024, the Audit Committee of the Board of Directors of the Company concluded a material impairment of the Company's interest in SGM was required based on a determination that a material loss in value of our investments in certain of the China JVs is other than temporary in light of the finalization of a new business forecast and certain restructuring actions that SGM is finalizing that are expected to be taken to address market challenges and competitive conditions. The Company is in the process of assessing the impact of SGM's planned restructuring actions and recent efforts to stabilize market share and focus on profitability, and expects to (i) record an other than temporary impairment of our equity interest in the China JVs in the range of $2.6-2.9B in the three months ending December 31, 2024, and (ii) recognize additional equity losses of approximately $2.7B resulting from the implementation of SGM's restructuring plan, which include impairment charges to be recognized by the China JVs related to plant closures and portfolio optimization, the majority of which we expect to record in the three months ending December 31, 2024. The charges are expected to be non-cash in nature and treated as special for EBIT-adjusted purposes." Reference Link

06:05 EST Walmart completes $2.3B acquisition of Vizio - Walmart (WMT) on Tuesday announced the completion of the company's acquisition of VIZIO (VZIO). The closing of the deal follows the expiration of the waiting period under federal regulations. "VIZIO offers great products at great prices that customers love. They've always put customers at the center of their business - and that's core to Walmart's values and the omnichannel experiences we're excited to roll out," said Seth Dallaire, executive vice president and chief growth officer, Walmart U.S. "VIZIO has also expertly changed their business over time, like building and quickly scaling a profitable advertising business. Pairing it with Walmart Connect will be impactful and allow us to invest in our business even further on behalf of our customers." As announced Feb. 20, Walmart signed a deal to acquire VIZIO and its SmartCast Operating System for $11.50 per share in cash, equating to a fully diluted equity value of approximately $2.3B. Walmart and VIZIO will continue to operate separately for the foreseeable future. William Wang will continue to lead VIZIO as CEO, reporting to Dallaire. Due to certain transaction-related costs associated with the acquisition, Walmart expects the transaction to be slightly dilutive to EPS both in the fourth quarter of fiscal year 2025 and for fiscal year 2026. To finance the acquisition, Walmart plans to use cash and/or debt. Internal Rate of Return for this transaction is expected to be ahead of Walmart's reported return on investment.

05:49 EST BIT Mining announces continued commitment to self-mining Litecoin, Dogecoin - BIT Mining announced the company's continued commitment to self-mining Litecoin and Dogecoin alongside Bitcoin mining and its data center hosting businesses. As other crypto miners look to diversify revenue streams in a post-halving environment, the company said its expansion into Litecoin and Dogecoin has proved to be nearly three times more profitable than mining BTC alone.

05:39 EST NXP Semiconductors joint venture breaks ground at Singapore fab - VisionPower Semiconductor Manufacturing, or VSMC, the joint venture formed in September by Vanguard International Semiconductor Corporation and NXP Semiconductors celebrated breaking ground at the site of the joint venture's new 300mm wafer manufacturing facility in Tampines, Singapore. Construction of the VSMC fab is on-track, with initial production slated to begin in 2027. Upon the successful ramp of the initial phase, a second phase will be considered and developed pending future business development by VIS and NXP. With an expected output of 55,000 300mm wafers per month in 2029, the joint venture will create approximately 1,500 jobs while contributing to the development of the upstream and downstream supply chains, contributing to Singapore and the global semiconductor ecosystem. The fab will adopt a fully automated production model, integrating an Automated Material Handling System, or AMHS, and quality management through Artificial Intelligence applications.

05:27 EST Novavax to sell Czech Republic manufacturing facility to Novo Nordisk for $200M - Novavax (NVAX) announced that it has signed a definitive agreement to sell its manufacturing facility in Bohumil, Czech Republic to Novo Nordisk (NVO) for $200M. The agreement includes a transfer of assets, including a 150,000-square foot recombinant protein manufacturing facility with support buildings, along with the existing workforce and all related and required infrastructure. The agreement provides Novavax with non-dilutive capital. In addition to the $190M cash payment in 2024 and additional $10M in 2025, Novavax expects the sale of the facility to result in annual operating cost reductions of approximately $80M. Following closure of the agreement, expected by December 30, full responsibility for the manufacturing facility will be transferred to Novo Nordisk.

05:12 EST Himax announces $20M share repurchase program - Himax announced that its board of directors has approved a share buyback program. The program authorizes the company to repurchase up to $20M of the company's American Depository Shares, or ADSs, in the open market or through privately negotiated transactions. The program will take effect immediately, does not obligate Himax to repurchase any specific amount of ADSs and may be modified or suspended at the Company's discretion at any time.

05:07 EST NCR Atleos extends relationship with East of England Co-op - NCR Atleos announced that East of England Co-op has extended its relationship with Atleos to provide ATMs through the Cashzone Network across its stores. The East of England Co-op has grown to become one of the largest, independent businesses in East Anglia, with over 200 stores and 3,000 employees. As a member-owned cooperative, its shareholders are the customers who shop with them, reinforcing the organization's ties with the local community. NCR Atleos and East of England Co-op have built a relationship over the last 11 years. NCR Atleos operates more than 16,000 ATMs through the Cashzone Network across the UK.